

SEPTACLAV-625

Amoxicillin & Clavulanate Potassium Tablets USP (500 mg & 125 mg)



MODULE-1

ADMINISTRATIVE INFORMATION

1.3 PRODUCT INFORMATION

1.3.1 Summary of product Characteristic

==Enclosed==

CONFIDENTIAL PROPERTY OF THEON PHARMACEUTICALS LTD

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of product characteristics SEPTACLAV 625Amoxicillin & Clavulanate Potassium Tablets USP (500 mg & 125 mg):

1.0 Name of the medicinal product

1.1 Name of medicinal Product:

SEPTACLAV 625Amoxicillin & Clavulanate Potassium Tablets USP (500 mg & 125 mg)

1.2 Strength:

Amoxicillin 500 mg & Clavulanate 125 mg

1.3 Pharmaceutical form:

Solid Oral Dosage Form, Film Coated Tablets

2.0 Qualitative and quantitative composition

Each film coated tablet contains:

Amoxicillin Trihydrate USP
eq.to Amoxicillin.....500 mg
Diluted Potassium Clavulanate BP
eq. to Clavulanic acid125 mg
Excipientsq.s.
Approved color used

S No.	Ingredients	Grade	Qty. Per Tablet (mg)	Function
	Slugging			
1	Amoxicillin Trihydrate (Compacted)	USP	500.000	Active
2	Sodium Starch Glycolate	BP	3.000	Disintegrant
3	Croscarmellose Sodium	BP	4.000	Disintegrant
4	Colloidal Anhydrous Silica	BP	6.000	Glidant
5	Purified Talc	BP	5.000	Lubricant
6	Magnesium Stearate	BP	5.000	Glidant
	Lubrication			
7	Diluted Potassium Clavulanate eq. to clavulanic acid	BP	125.000	Active

8	*Microcrystalline Cellulose (MCC PH 112)	BP	386.000	Diluent
9	Purified Talc	BP	6.000	Lubricant
10	Magnesium Stearate	BP	10.000	Glidant
Seal coating Material				
11	Hypromellose	BP	8.600	Coating
12	Ethylcellulose	BP	3.200	Plasticizer for coating
13	Diethyl Phthalate	BP	3.200	
14	Isopropyl Alcohol	BP	q.s*	Solvent
15	Dichloromethane	BP	q.s*	Solvent
Film Coating Material				
16	Hypromellose	BP	10.000	Coating
17	Macrogol (Polyethylene Glycol 6000)	BP	9.000	Plasticizer for coating
18	Titanium Dioxide	BP	6.000	Colorant
19	Isopropyl Alcohol	BP	q.s*	Solvent
20	Dichloromethane	BP	q.s*	Solvent

3.0 Pharmaceutical form

White to off-white colored, capsule shaped biconvex, film coated tablet with break line on one side and other side plain.

Pack Style: A Strip containing 10 tablets packed in aluminium pouch which is further packed in a unit carton along with package insert.

4.0 Clinical particulars

4.1 Therapeutic indications

SEPTACLAV 625 is indicated for the treatment of the following infections in adults and children.

- Acute bacterial sinusitis (adequately diagnosed)
- Acute otitis media
- Acute exacerbations of chronic bronchitis (adequately diagnosed)

- Community acquired pneumonia
- Cystitis
- Pyelonephritis
- Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis
- Bone and joint infections, in particular osteomyelitis.

4.2 Posology and method of administration

Doses are expressed throughout in terms of amoxicillin/clavulanic acid content except when doses are stated in terms of an individual component.

The dose of SEPTACLAV 625 that is selected to treat an individual infection should take into account:

- The expected pathogens and their likely susceptibility to antibacterial agents
- The severity and the site of the infection
- The age, weight and renal function of the patient as shown below.

The use of alternative presentations of X-clav (e.g. those that provide higher doses of amoxicillin and/or different ratios of amoxicillin to clavulanic acid) should be considered as necessary.

For adults and children ≥ 40 kg, this formulation of SEPTACLAV 625 provides a total daily dose of 1500 mg amoxicillin/375 mg clavulanic acid, when administered as recommended below. For children < 40 kg, this formulation of SEPTACLAV 625 provides a maximum daily dose of 2400 mg amoxicillin/600 mg clavulanic acid, when administered as recommended below. If it is considered that a higher daily dose of amoxicillin is required, it is recommended that another preparation of SEPTACLAV 625 is selected in order to avoid administration of unnecessarily high daily doses of clavulanic acid.

The duration of therapy should be determined by the response of the patient. Some infections (e.g. osteomyelitis) require longer periods of treatment. Treatment should not be extended beyond 14 days without review.

Adults and children ≥ 40 kg

One 500 mg/125 mg dose taken three times a day.

Children < 40 kg

20 mg/5 mg/kg/day to 60 mg/15 mg/kg/day given in three divided doses.

Children may be treated with X-clav tablets or suspensions.

As the tablets cannot be divided, children weighing less than 25 kg must not be treated with SEPTACLAV 625 tablets.

The table below presents the received dose (mg/kg body weight) in children weighing 25 kg to 40 kg upon administering a single 500/125 mg tablet.

Body weight [kg]	40	35	30	25	Single dose recommended [mg/kg body weight]
Amoxicillin [mg/kg body weight] per single dose (1 film-coated tablet)	12.5	14.3	16.7	20.0	6.67 – 20
Clavulanic acid [mg/kg body weight] per single dose (1 film-coated tablet)	3.1	3.6	4.2	5.0	1.67 - 5

Children aged 6 years and below or weighing less than 25 kg should preferably be treated with X-clav suspension.

Elderly

No dose adjustment is considered necessary.

Renal impairment

Dose adjustments are based on the maximum recommended level of amoxicillin.

No adjustment in dose is required in patients with creatinine clearance (CrCl) greater than 30 ml/min.

Adults and children \geq 40 kg

CrCl: 10-30 ml/min	500 mg/125 mg twice daily
CrCl < 10 ml/min	500 mg/125 mg once daily
Haemodialysis	500 mg/125 mg every 24 hours, plus 500 mg/125 mg during dialysis, to be repeated at the end of dialysis (as serum concentrations of both amoxicillin and clavulanic acid are decreased)

Children < 40 kg

CrCl: 10-30 ml/min	15 mg/3.75 mg/kg twice daily (maximum 500 mg/125 mg twice daily).
CrCl < 10 ml/min	15 mg/3.75 mg/kg as a single daily dose (maximum 500 mg/125 mg).
Haemodialysis	15 mg/3.75 mg/kg per day once daily. Prior to haemodialysis 15 mg/3.75 mg/kg. In order to restore circulating drug levels, 15 mg/3.75 mg per kg should be administered after haemodialysis.

Hepatic impairment

Dose with caution and monitor hepatic function at regular intervals.

Method of administration

SEPTACLAV 625 is for oral use.

Administer at the start of a meal to minimise potential gastrointestinal intolerance and optimise absorption of amoxicillin/clavulanic acid.

4.3 Contraindications

Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients.

History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).

History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid

4.4 Special warnings and precautions for use

Before initiating therapy with amoxicillin/clavulanic acid, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other beta-lactam agents.

Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and in atopic individuals. If an allergic reaction occurs, amoxicillin/clavulanic acid therapy must be discontinued and appropriate alternative therapy instituted.

In the case that an infection is proven to be due to an amoxicillin-susceptible organisms(s) then consideration should be given to switching from amoxicillin/clavulanic acid to amoxicillin in accordance with official guidance.

This presentation of SEPTACLAV 625 is not suitable for use when there is a high risk that the presumptive pathogens have reduced susceptibility or resistance to beta-lactam agents that is not mediated by beta-lactamases susceptible to inhibition by clavulanic acid (e.g. *penicillin-insusceptible S. pneumoniae*).

Convulsions may occur in patients with impaired renal function or in those receiving high doses Amoxicillin/clavulanic acid should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.

Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.

Prolonged use may occasionally result in overgrowth of non-susceptible organisms. The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthemous pustulosis (AGEP). This reaction requires SEPTACLAV 625 discontinuation and contra-indicates any subsequent administration of amoxicillin.

4.5 Interaction with other medicinal products and other forms of interaction

Oral anticoagulants

Oral anticoagulants and penicillin antibiotics have been widely used in practice without reports of interaction. However, in the literature there are cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co-administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of amoxicillin. Moreover, adjustments in the dose of oral anticoagulants may be necessary.

Methotrexate

Penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity.

Probenecid

Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concomitant use of probenecid may result in increased and prolonged blood levels of amoxicillin but not of clavulanic acid.

Mycophenolate mofetil

In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid (MPA) of approximately 50% has been reported following commencement of oral amoxicillin plus clavulanic acid. The change in pre-dose level may not accurately represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.

4.6 Pregnancy and lactation

Pregnancy

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Limited data on the use of amoxicillin/clavulanic acid during pregnancy in humans do not indicate an increased risk of congenital malformations. In a single study in women with preterm, premature rupture of the foetal membrane it was reported that prophylactic treatment with amoxicillin/clavulanic acid may be associated with an increased risk of necrotising enterocolitis in neonates. Use should be avoided during pregnancy, unless considered essential by the physician.

Lactation

Both substances are excreted into breast milk (nothing is known of the effects of clavulanic acid on the breast-fed infant). Consequently, diarrhoea and fungus infection of the mucous membranes are possible in the breast-fed infant, so that breast-feeding might have to be discontinued. Amoxicillin/clavulanic acid should only be used during breast-feeding after benefit/risk assessment by the physician in charge.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. allergic reactions, dizziness, convulsions), which may influence the ability to drive and use machines.

4.8 Undesirable effects

The most commonly reported adverse drug reactions (ADRs) are diarrhoea, nausea and vomiting.

The ADRs derived from clinical studies and post-marketing surveillance, sorted by Med DRA System Organ Class are listed below.

The following terminologies have been used in order to classify the occurrence of undesirable effects.

Very common ($\geq 1/10$)

Common ($\geq 1/100$ to $<1/10$)

Uncommon ($\geq 1/1,000$ to $<1/100$)

Rare ($\geq 1/10,000$ to $<1/1,000$)

Very rare ($<1/10,000$)

Not known (cannot be estimated from the available data)

<u>Infections and infestations</u>	
Mucocutaneous candidosis	Common
Overgrowth of non-susceptible organisms	Not known
<u>Blood and lymphatic system disorders</u>	
Reversible leucopenia (including neutropenia)	Rare
Thrombocytopenia	Rare
Reversible agranulocytosis	Not known
Haemolytic anaemia	Not known
Prolongation of bleeding time and prothrombin time ¹	Not known
<u>Immune system disorders</u> ¹⁰	
Angioneurotic oedema	Not known
Anaphylaxis	Not known
Serum sickness-like syndrome	Not known
Hypersensitivity vasculitis	Not known
<u>Nervous system disorders</u>	
Dizziness	Uncommon
Headache	Uncommon
Reversible hyperactivity	Not known
Convulsions ²	Not known
<u>Gastrointestinal disorders</u>	
Diarrhoea	Very common
Nausea ³	Common
Vomiting	Common
Indigestion	Uncommon
Antibiotic-associated colitis ⁴	Not known
Black hairy tongue	Not known
<u>Hepatobiliary disorders</u>	
Rises in AST and/or ALT ⁵	Uncommon
Hepatitis ⁶	Not known

Cholestatic jaundice ⁶	Not known
<u>Skin and subcutaneous tissue disorders</u> ⁷	
Skin rash	Uncommon
Pruritus	Uncommon
Urticaria	Uncommon
Erythema multiforme	Rare
Stevens-Johnson syndrome	Not known
Toxic epidermal necrolysis	Not known
Bullous exfoliative-dermatitis	Not known
Acute generalised exanthemous pustulosis (AGEP) ⁹	Not known
<u>Renal and urinary disorders</u>	
Interstitial nephritis	Not known
Crystalluria ⁸	Not known
¹ See section Warning and precautions ² See section Warning and precautions ³ Nausea is more often associated with higher oral doses. If gastrointestinal reactions are evident, they may be reduced by taking SEPTACLAV 625 at the start of a meal. ⁴ Including pseudomembranous colitis and haemorrhagic colitis ⁵ A moderate rise in AST and/or ALT has been noted in patients treated with beta-lactam class antibiotics, but the significance of these findings is unknown. ⁶ These events have been noted with other penicillins and cephalosporins ⁷ If any hypersensitivity dermatitis reaction occurs, treatment should be discontinued ⁸ See section Overdose ⁹ See section Warning and precautions ¹⁰ See sections Contra-indications and Warning and precautions	

4.9 Overdose

Symptoms and signs of overdose

Gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Amoxicillin crystalluria, in some cases leading to renal failure, has been observed. Convulsions may occur in patients with impaired renal function or in those receiving high doses. Amoxicillin has been reported to precipitate in bladder catheters, predominantly after intravenous administration of large doses. A regular check of patency should be maintained.

Treatment of intoxication

Gastrointestinal symptoms may be treated symptomatically, with attention to the water/electrolyte balance.

Amoxicillin/clavulanic acid can be removed from the circulation by haemodialysis.

5 Pharmacological properties

5.1 Pharmacodynamics properties

Pharmacotherapeutic group: Combinations of penicillins, incl. beta-lactamase inhibitors

ATC code: J01CR02

Mode of action

Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death.

Amoxicillin is susceptible to degradation by beta-lactamases produced by resistant bacteria and therefore the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.

Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. Clavulanic acid alone does not exert a clinically useful antibacterial effect.

PK/PD relationship

The time above the minimum inhibitory concentration ($T > MIC$) is considered to be the major determinant of efficacy for amoxicillin.

Mechanism of resistance

The two main mechanisms of resistance to amoxicillin/clavulanic acid are:

- Inactivation by those bacterial beta-lactamases that are not themselves inhibited by clavulanic acid, including class B, C and D.
- Alteration of PBPs, which reduce the affinity of the antibacterial agent for the target.

Impermeability of bacteria or efflux pump mechanisms may cause or contribute to bacterial resistance, particularly in Gram-negative bacteria.

Breakpoints

MIC breakpoints for amoxicillin/clavulanic acid are those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)

Organism	Susceptibility Breakpoints ($\mu\text{g/ml}$)		
	Susceptible	Intermediate	Resistant
<i>Haemophilus influenzae</i> ¹	≤ 1	-	> 1

<i>Moraxella catarrhalis</i> ¹	≤ 1	-	> 1
<i>Staphylococcus aureus</i> ²	≤ 2	-	> 2
Coagulase-negative staphylococci ²	≤ 0.25		> 0.25
<i>Enterococcus</i> ¹	≤ 4	8	> 8
<i>Streptococcus A, B, C, G</i>	≤ 0.25	-	> 0.25
<i>Streptococcus pneumoniae</i> ³	≤ 0.5	1-2	> 2
Enterobacteriaceae ^{1,4}	-	-	> 8
Gram-negative Anaerobes ¹	≤ 4	8	> 8
Gram-positive Anaerobes ¹	≤ 4	8	> 8
Non-species related breakpoints ¹	≤ 2	4-8	> 8

¹ The reported values are for Amoxicillin concentrations. For susceptibility testing purposes, the concentration of Clavulanic acid is fixed at 2 mg/l.

² The reported values are Oxacillin concentrations.

³ Breakpoint values in the table are based on Ampicillin breakpoints.

⁴ The resistant breakpoint of R>8 mg/l ensures that all isolates with resistance mechanisms are reported resistant.

⁵ Breakpoint values in the table are based on Benzylpenicillin breakpoints.

The prevalence of resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

<u>Commonly susceptible species</u>
<u>Aerobic Gram-positive micro-organisms</u>
<i>Enterococcus faecalis</i>
<i>Gardnerella vaginalis</i>
<i>Staphylococcus aureus</i> (methicillin-susceptible)£
Coagulase-negative staphylococci (methicillin-susceptible)
<i>Streptococcus agalactiae</i>
<i>Streptococcus pneumoniae</i> ¹
<i>Streptococcus pyogenes</i> and other beta-haemolytic streptococci
<i>Streptococcus viridans</i> group
<u>Aerobic Gram-negative micro-organisms</u>
<i>Capnocytophaga</i> spp.
<i>Eikenella corrodens</i>
<i>Haemophilus influenzae</i> ²
<i>Moraxella catarrhalis</i>
<i>Pasteurella multocida</i>
<u>Anaerobic micro-organisms</u>
<i>Bacteroides fragilis</i>
<i>Fusobacterium nucleatum</i>
<i>Prevotella</i> spp.

<u>Species for which acquired resistance may be a problem</u>
<u>Aerobic Gram-positive micro-organisms</u> <i>Enterococcus faecium</i> § <u>Aerobic Gram-negative micro-organisms</u> <i>Escherichia coli</i> <i>Klebsiella oxytoca</i> <i>Klebsiella pneumoniae</i> <i>Proteus mirabilis</i> <i>Proteus vulgaris</i>
<u>Inherently resistant organisms</u>
<u>Aerobic Gram-negative micro-organisms</u> <i>Acinetobacter</i> sp. <i>Citrobacter freundii</i> <i>Enterobacter</i> sp. <i>Legionella pneumophila</i> <i>Morganella morganii</i> <i>Providencia</i> spp. <i>Pseudomonas</i> sp. <i>Serratia</i> sp. <i>Stenotrophomonas maltophilia</i> <u>Other micro-organisms</u> <i>Chlamydophila pneumoniae</i> <i>Chlamydophila psittaci</i> <i>Coxiella burnetii</i> <i>Mycoplasma pneumoniae</i>
§ Natural intermediate susceptibility in the absence of acquired mechanism of resistance. £All methicillin-resistant staphylococci are resistant to amoxicillin/clavulanic acid ¹ <i>Streptococcus pneumoniae</i> that are resistant to penicillin should not be treated with this presentation of amoxicillin/clavulanic acid. ² Strains with decreased susceptibility have been reported in some countries in the EU with a frequency higher than 10%.

5.2 Pharmacokinetic properties

Absorption

Amoxicillin and clavulanic acid, are fully dissociated in aqueous solution at physiological pH. Both components are rapidly and well absorbed by the oral route of administration. Absorption of amoxicillin/clavulanic acid is optimized when taken at the start of a meal. Following oral administration, amoxicillin and clavulanic acid are approximately 70% bioavailable. The plasma profiles of both components are similar and the time to peak plasma concentration (T_{max}) in each case is approximately one hour.

The pharmacokinetic results for a study, in which amoxicillin/clavulanic acid (875 mg/125 mg tablets given twice daily) was administered in the fasting state to groups of healthy volunteers are presented below.

Mean (\pm SD) pharmacokinetic parameters					
Active substance(s) administered	Dose	C_{max}	T_{max}^*	AUC _(0-24h)	T 1/2
	(mg)	(μ g/ml)	(h)	((μ g.h/ml)	(h)
Amoxicillin					
AMX/CA 250 mg/125 mg	250	3.3 \pm 1.12	1.5 (1.0-2.0)	26.7 4. 6	1.36 \pm 0.56
Clavulanic acid					
AMX/CA 250 mg/125 mg	125	1.5 \pm 0.70	1.2 (1.0-2.0)	12.6 \pm 3.25	1.01 \pm 0.11
AMX – amoxicillin, CA – clavulanic acid Median (range)					

Amoxicillin and clavulanic acid serum concentrations achieved with amoxicillin/clavulanic acid are similar to those produced by the oral administration of equivalent doses of amoxicillin or clavulanic acid alone.

Distribution

About 25% of total plasma clavulanic acid and 18% of total plasma amoxicillin is bound to protein. The apparent volume of distribution is around 0.3-0.4 l/kg for amoxicillin and around 0.2 l/kg for clavulanic acid. Following intravenous administration, both amoxicillin and clavulanic acid have been found in gall bladder, abdominal tissue, skin, fat, muscle tissues, synovial and peritoneal fluids, bile and pus. Amoxicillin does not adequately distribute into the cerebrospinal fluid.

From animal studies there is no evidence for significant tissue retention of drug-derived material for either component. Amoxicillin, like most penicillins, can be detected in breast milk. Trace quantities of clavulanic acid can also be detected in breast milk. Both amoxicillin and clavulanic acid have been shown to cross the placental barrier.

Biotransformation

Amoxicillin is partly excreted in the urine as the inactive penicilloic acid in quantities equivalent to up to 10 to 25% of the initial dose. Clavulanic acid is extensively metabolized in man and eliminated in urine and faeces and as carbon dioxide in expired air.

Metabolism

Amoxicillin is partly excreted in the urine as the inactive penicilloic acid in quantities equivalent to up to 10 to 25% of the initial dose. Clavulanic acid is extensively metabolized in man and eliminated in urine and faeces and as carbon dioxide in expired air

Elimination

The major route of elimination for amoxicillin is via the kidney, whereas for clavulanic acid it is by both renal and non-renal mechanisms. Amoxicillin/clavulanic acid has a mean elimination half-life of approximately one hour and a mean total clearance of approximately 25 l/h in healthy subjects. Approximately 60 to 70% of the amoxicillin and approximately 40 to 65% of the clavulanic acid are excreted unchanged in urine during the first 6 h after administration of single Amoxicillin/clavulanic acid 250 mg/125 mg or 500 mg/125 mg tablets. Various studies have found the urinary excretion to be 50-85% for amoxicillin and between 27-60% for clavulanic acid over a 24 hour period. In the case of clavulanic acid, the largest amount of drug is excreted during the first 2 hours after administration. Concomitant use of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid.

Special patient populations

Age

The elimination half-life of amoxicillin is similar for children aged around 3 months to 2 years and older children and adults. For very young children (including preterm newborns) in the first week of life the interval of administration should not exceed twice daily administration due to immaturity of the renal pathway of elimination. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Gender

Following oral administration of amoxicillin/clavulanic acid to healthy males and female subjects, gender has no significant impact on the pharmacokinetics of either amoxicillin or clavulanic acid.

Renal impairment

The total serum clearance of amoxicillin/clavulanic acid decreases proportionately with decreasing renal function. The reduction in drug clearance is more pronounced for amoxicillin than for clavulanic acid, as a higher proportion of amoxicillin is excreted *via* the renal route. Doses in renal impairment must therefore prevent undue accumulation of amoxicillin while maintaining adequate levels of clavulanic acid.

Hepatic impairment

Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals.

5.3 Preclinical safety data

Nonclinical data reveal no special hazard for humans based on studies of safety pharmacology, genotoxicity and toxicity to reproduction.

Repeat dose toxicity studies performed in dogs with amoxicillin/clavulanic acid demonstrate gastric irritancy and vomiting, and discoloured tongue.

Carcinogenicity studies have not been conducted with Augmentin or its components.

6 Pharmaceutical particulars

6.1 List of excipients

Following excipients are used in **SEPTACLAV 625** (Amoxicillin & Clavulanate Potassium Tablets USP (500 mg & 125 mg))

Ingredients
Sodium Starch Glycolate
Croscarmellose Sodium
Colloidal Anhydrous Silica
Purified Talc
Magnesium Stearate
Hypromellose (Hydroxypropylmethylcellulose E-5)
Ethylcellulose
Hypromellose
Titanium Dioxide
Diethyl Phthalate
Macrogol (Polyethylene Glycol 6000)
Isopropyl Alcohol
Dichloromethane

6.2 Incompatibilities

None reported from clinical studies

6.3 Shelf life

24 Months

6.4 Special precautions for storage

Store below 30°C. Protect from light and moisture.

6.5 Nature and contents of container

Solid oral dosage form, Film coated tablets.

A Strip containing 10 tablets packed in aluminium pouch which is further packed in a unit carton along with package insert.

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing Authorization holder

Not applicable

8. Marketing authorization number(s)

Not applicable

9. Date of first authorisation/renewal of the authorisation

Not applicable

10. Date of revision of the text

Not applicable